Education only · provider review required
CJC-1295 · GHRH analog research context
An educational overview of what researchers have and have not established about CJC-1295. Education only · provider review required.
Medically reviewed by Bernard Garcia, MD
What it is
CJC-1295 is a synthetic peptide described in the scientific literature as an analog of growth-hormone-releasing hormone (GHRH). It is studied as a modified GHRH fragment engineered for increased stability, and some formulations discussed in research are designed to extend the peptide's presence in circulation.
Research interest in CJC-1295 centers on the growth-hormone axis and on how modifications to a GHRH analog affect its behavior in experimental models. This page summarizes that framing and does not describe any therapeutic use, dose, or outcome.
How it works
Mechanistically, CJC-1295 is discussed in the literature as an agonist at the GHRH receptor on the pituitary, which researchers associate with stimulation of growth-hormone release in experimental models.
A distinguishing feature described in published work is the engineering intended to prolong the analog's activity relative to native GHRH, a property researchers study in relation to how growth-hormone release is patterned over time. Whether these laboratory characterizations carry any clinical significance has not been established here and remains a matter for qualified researchers and licensed providers to evaluate.
Research status
| Research area | Status |
|---|---|
| GHRH-analog pharmacology | Studied as a modified GHRH fragment engineered for stability |
| Pituitary secretion dynamics | Examined for growth-hormone release in experimental models |
| Duration-of-action research | Discussed in relation to prolonged activity versus native GHRH |
| Safety and long-term outcomes | Not established; requires evaluation by qualified researchers and licensed providers |
Status reflects published research context only and is not a statement of safety, efficacy, or suitability for any person.
Is it legal?
Regulatory status varies by country and can change. CJC-1295 is studied as a research peptide and is not an approved medicine in general consumer contexts; its availability and permitted uses should be confirmed against current official sources rather than assumed. Nothing on this page is a claim about approval, safety, or suitability for any purpose.
This material is provided for education only. A licensed provider determines appropriateness after a confidential intake. Education only · provider review required.
Frequently asked questions
What is CJC-1295?
It is a synthetic GHRH analog studied as a modified, stability-enhanced fragment of growth-hormone-releasing hormone. This page is educational and not a recommendation for use.
How is it different from native GHRH?
The literature describes CJC-1295 as engineered for greater stability and prolonged activity relative to native GHRH. The significance of that difference is a matter for qualified researchers and licensed providers.
Is CJC-1295 appropriate for me?
This page cannot answer that. A licensed provider determines appropriateness only after a confidential intake and review of your individual circumstances.
Where do the research claims come from?
The research summary on this page links to a primary source record for this compound, such as its public NIH database entry, where applicable. This page is educational only and is not a substitute for advice from a licensed provider.
Next step
Next step: a 3-minute confidential intake, reviewed by a licensed provider. No treatment is promised or implied.
Free · about 10 minutes · reviewed by a licensed physician
General education · Not medical advice · Provider approval required